PHARMAC work in funding medicines for rare disorders progressing

16 July 2018
2019_biotech_test_vial_discovery_big

New Zealand’s Pharmaceutical Management Agency PHARMAC said today that is progressing work aimed at improving funded access to medicines for rare disorders.

Chief executive Sarah Fitt says the latest step is the appointment of a clinical subcommittee with expertise in evaluating medicines for rare disorders. The subcommittee, which includes leading New Zealand and Australian experts in managing patients with rare disorders, will provide advice to PHARMAC’s main clinical committee, PTAC.

Earlier in the month, PHARMAC published updated policy settings for assessing medicines for rare disorders, and opened a commercial process seeking funding applications from pharmaceutical suppliers, specifically for medicines for rare disorders.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology